SG11201900501RA - Cannabis composition - Google Patents

Cannabis composition

Info

Publication number
SG11201900501RA
SG11201900501RA SG11201900501RA SG11201900501RA SG11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA SG 11201900501R A SG11201900501R A SG 11201900501RA
Authority
SG
Singapore
Prior art keywords
international
bay
western australia
perth
pct
Prior art date
Application number
SG11201900501RA
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65524553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201900501R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2017901222A external-priority patent/AU2017901222A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of SG11201900501RA publication Critical patent/SG11201900501RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201900501RA 2016-08-03 2017-08-03 Cannabis composition SG11201900501RA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662370299P 2016-08-03 2016-08-03
AU2017901222A AU2017901222A0 (en) 2017-04-04 Cannabis composition
AU2017902065A AU2017902065A0 (en) 2017-05-31 Cannabis composition
PCT/AU2017/050817 WO2018023166A1 (fr) 2016-08-03 2017-08-03 Composition de cannabis

Publications (1)

Publication Number Publication Date
SG11201900501RA true SG11201900501RA (en) 2019-02-27

Family

ID=65524553

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900501RA SG11201900501RA (en) 2016-08-03 2017-08-03 Cannabis composition

Country Status (15)

Country Link
US (2) US11304925B1 (fr)
EP (1) EP3493800A4 (fr)
JP (2) JP2019526541A (fr)
KR (3) KR20190034576A (fr)
CN (1) CN109789123A (fr)
AU (4) AU2017305103B2 (fr)
BR (1) BR112019001794A2 (fr)
CA (1) CA3031300A1 (fr)
CL (1) CL2019000266A1 (fr)
CO (1) CO2019001043A2 (fr)
IL (1) IL264458B (fr)
MX (1) MX2019001286A (fr)
PE (2) PE20200677A1 (fr)
SG (1) SG11201900501RA (fr)
WO (1) WO2018023166A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019523283A (ja) 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
US10668044B2 (en) * 2017-06-27 2020-06-02 William H. Muscarella Blended cannabis compounds and methods of making the same
AU2018101357B4 (en) * 2017-09-15 2022-03-17 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
EP3745884A1 (fr) 2018-01-31 2020-12-09 Canopy Holdings, Llc Poudre de chanvre
AU2019251357B2 (en) * 2018-04-09 2023-10-05 Portland Technology Holdings Llc Hemp extract for treatment of pain in animals
WO2019227167A1 (fr) * 2018-06-01 2019-12-05 The University Of Sydney Compositions et traitements
WO2019240581A1 (fr) * 2018-06-14 2019-12-19 Biosoma B.V. Procédé d'extraction de composants solubles dans l'huile issus d'une matière végétale
EP3864000A4 (fr) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. Synthèse du cannabigérol
WO2020084423A1 (fr) * 2018-10-24 2020-04-30 Radient Technologies Innovations Inc. Exécution de contrat axé sur l'extraction
CA3123773A1 (fr) * 2018-12-12 2020-06-18 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions et procedes pour le traitement d'un lymphome cutane a cellules t (ctcl)
CA3154295A1 (fr) * 2019-10-09 2021-04-15 Michael Foster DAVIS Materiau aerosolisable
EP4142929A4 (fr) * 2020-04-29 2024-02-21 Ligar Lp Polymères à empreinte et procédés pour leur utilisation
MX2022015799A (es) * 2020-06-12 2023-04-11 Zelira Therapeutics Operations Pty Ltd Composicion y metodo para el tratamiento del dolor cronico.
WO2022191551A1 (fr) * 2021-03-08 2022-09-15 주식회사 엘지생활건강 Composition comprenant du cannabigérol
IL307444A (en) * 2021-04-05 2023-12-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Preparations and methods for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
AU2005314021B2 (en) 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2007032962A2 (fr) 2005-09-09 2007-03-22 University Of Kentucky Compositions et procédés destinés à une administration intranasale de cannabidoïdes tricycliques
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB201117956D0 (en) * 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
JP2015515977A (ja) * 2012-05-03 2015-06-04 エコ・ファーマシューティカルズ・ビー．ブイ．Ｅｃｈｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． Δ９−テトラヒドロカンナビノールを含む大麻草単離物及びこのような単離物を製造するための方法
WO2014159688A1 (fr) 2013-03-14 2014-10-02 Sc Laboratories, Inc. Concentrés bioactifs et leurs utilisations
MX2015013202A (es) 2013-03-15 2016-04-07 Biotech Inst Llc Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
DK3062606T3 (da) * 2013-10-29 2019-06-24 Biotech Inst Llc Forædling, fremstilling, forarbejdning og anvendelse af speciel cannabis
US9044390B1 (en) 2014-04-17 2015-06-02 Gary J. Speier Pharmaceutical composition and method of manufacturing
WO2015200049A1 (fr) 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Produits associés à un aérosol doseur, et procédés d'utilisation
WO2016030369A1 (fr) * 2014-08-25 2016-03-03 Janing Holding Aps Dispositif avec des compositions pour administration aux poumons, à la muqueuse buccale et au cerveau
EP3209312A1 (fr) * 2014-10-21 2017-08-30 United Cannabis Corp. Extraits de cannabis et procédés de préparation et d'utilisation
EA201791299A1 (ru) * 2014-12-12 2017-12-29 ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи Микроинкапсулированные композиции каннабиноидов
WO2016105514A1 (fr) * 2014-12-23 2016-06-30 Biotech Institute, Llc Procédé fiable et robuste d'analyse des cannabinoïdes et des terpènes dans le cannabis
US10406186B2 (en) * 2015-01-31 2019-09-10 Constance Therapeutics, Inc. Cannabis oil extracts and compositions
US20190307719A1 (en) 2016-08-03 2019-10-10 Zelda Therapeutics Operations Pty Ltd Cannabis composition
JP2019523283A (ja) 2016-08-03 2019-08-22 ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド 大麻組成物

Also Published As

Publication number Publication date
KR102447510B1 (ko) 2022-09-27
AU2019203529A1 (en) 2019-06-06
KR20220132674A (ko) 2022-09-30
CN109789123A (zh) 2019-05-21
KR20190034576A (ko) 2019-04-02
PE20230607A1 (es) 2023-04-13
AU2018100920B4 (en) 2019-02-07
CL2019000266A1 (es) 2019-10-04
WO2018023166A1 (fr) 2018-02-08
AU2021205115A1 (en) 2021-08-12
AU2017305103A1 (en) 2018-07-05
EP3493800A4 (fr) 2020-04-08
PE20200677A1 (es) 2020-06-11
MX2019001286A (es) 2019-06-13
JP2019526541A (ja) 2019-09-19
CO2019001043A2 (es) 2020-06-19
AU2018100920A4 (en) 2018-08-02
IL264458A (en) 2019-02-28
EP3493800A1 (fr) 2019-06-12
CA3031300A1 (fr) 2018-02-08
BR112019001794A2 (pt) 2019-05-07
US20220202767A1 (en) 2022-06-30
IL264458B (en) 2021-06-30
AU2017305103B2 (en) 2019-02-21
JP7139559B2 (ja) 2022-09-21
AU2019203529B2 (en) 2021-04-29
KR20210129747A (ko) 2021-10-28
US11304925B1 (en) 2022-04-19
NZ750272A (en) 2021-09-24
JP2021054836A (ja) 2021-04-08
AU2021205115B2 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
SG11201900501RA (en) Cannabis composition
SG11201900596XA (en) Cannabis composition
SG11201900665VA (en) Cannabis composition
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201804118VA (en) Compositions comprising bacterial strains
SG11201804211YA (en) Compositions comprising bacterial strains
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201907867TA (en) Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201803834UA (en) Methods for treating conditions associated with masp-2 dependent complement activation
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201901172QA (en) A method for manufacturing a fuel component
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201909837YA (en) Methods for treating lung disorders
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate